Novavax confirms high levels of efficacy of its Covid-19 vaccine (NVX–CoV2373) against original and variant COVID-19 strains in UK and South Africa trials

A UK Phase III trial of its Covid-19 vaccine showed a final efficacy of 96.4% against mild, moderate and severe disease caused by the original COVID-19 strain. In the Phase 2b trial in South Africa, efficacy was 55.4% in a region where most strains wee B1.351 escape variants.

Biospace Inc.